Replies to post #77451 on Cytodyn Inc (CYDY)

[Chuckles759]

First Lenzilumab patient dosed on 06May20....Leronlimab is a few hairs ahead of them. Humanigen is at least a couple of weeks from announcing preliminary data. We shall hopefully see how it stacks up.

The race is on.


https://www.proactiveinvestors.com/companies/news/918986/humanigen-sees-first-coronavirus-patient-treated-in-phase-3-trial-of-lenzilumab-918986.html

[Blane]

Not sure the full MOA, but this monoclonal antibody appears to be more limited in its MOA, and potentially not nearly as broad acting as Leronlimab. Leronlimab is like attacking the tree at the trunk, whereas lenzilumab Is

“A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.”

That doesn’t mean that it may not have good cancer applications. It just seems to be way more limited than Leronlimab, particularly in taking the cytokine storm.

Just my opinion.

[BioInvestor4]

The problem with HGEN is they haven’t released a single thing as far as data, even from their Emergency IND patients.. so there’s no way to even see the effectiveness on those patirnts. No data available what so ever

[tcbush]

EIDD-2801 looks promising though it is an antiviral I believe similar to Remdesivir. Still In early trials but seems to have a positive outlook based on articles I have read.

[Borel Fields]

Add the CytoSorb blood filter from CytoSorbents to the list of cytokine treatments. This snaps in to a dialysis machine - been used 80k times in Europe/Asia in surgeries likely to trigger a storm - does what it says. Here are their COVID comments from their earnings call:

"and in the first quarter, we treated the first 70 COVID-19 patients, including the very first patients treated in China with partner China Medical Systems Holding Limited of now more than 750 patients treated, including 25 under the US FDA Emergency Use Authorization."

The stock dipped as low as $4 late March, now $10.40 - up 40% since I took profits to put all my bets on CYDY.